XTALPi Holdings (02228.HK) Surges Over 4% as ReviR's Innovative Drug RTX-117 Receives IND Approvals in Both China and the U.S.

According to the Zhongtong Finance APP, XtalPi Holdings Limited (02228) surged over 4% again, with cumulative gains approaching 50% this month. As of press time, it rose by 4.68%, trading at HK$14.08, with a turnover of HK$6.65 billion.

On the news front, XtalPi announced that its incubated company ReviR Therapeutics' innovative drug pipeline RTX-117 has recently achieved the milestone of "dual filing and dual approval" (IND approval) in both China and the U.S. Combined with the successful progress of multiple collaborations, XtalPi will receive milestone payments totaling several tens of millions of Hong Kong dollars from ReviR. ReviR will continue to complete the subsequent clinical development of RTX-117, and XtalPi has the right to participate in the sales revenue sharing and subsequent licensing revenue sharing of this pipeline.

Guolian Minsheng Securities released a research report stating that XtalPi Holdings has established a moat with its software and hardware technology accumulation, platform-based business model, and strategic positioning in key sectors within the AI pharmaceutical field. The firm believes that the clinical approval of RTX-117 marks the entry of its technology platform into a value realization phase. As its collaborative pipeline continues to expand, there is significant potential for earnings growth and valuation reevaluation.